Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Determining whether ion-channels influence the response to brain cancer therapeutics

Terrance Brittany Johns Dewdney BSc, MBSc, PhD Honorary Research Associate Postdoctoral Researcher brittany.dewdney@thekids.org.au Honorary Research

Research

The role of voltage-gated sodium channels in high grade glioma

Every year, around 1,500 Australians are diagnosed with brain cancer, and many of them die due to a lack of effective treatments.

Research

Asymptomatic CMV infections in long-term renal transplant recipients are associated with the loss of FcRγ from LIR-1+ NK cells

CMV can be reactivated in symptom-free renal transplant recipients, affecting the phenotypic, and functional profiles of NK cells

Research

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

Our results show that TRM cells have a fundamental role in the surveillance of subclinical melanomas in the skin by maintaining cancer-immune equilibrium

Research

PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours

Our findings define PTPN2 as a target for bolstering T-cell-mediated anti-tumour immunity and CAR T-cell therapy against solid tumours.

Research

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

Our results identify a pretreatment tumor microenvironment that predicts response to immune checkpoint blockade, which can be therapeutically attained

Research

Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens

These findings suggest that tumor cells employ multiple epigenetic and genetic mechanisms to evade immune control

Research

Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3

These findings implicate the activation of STAT3 as one pathway that may mediate resistance to IGF-II-targeted therapy in HCC

Research

Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients

All children who are receiving therapy for cancer should receive a single dose of PCV13 as soon as possible after diagnosis, regardless of prior PCV exposure.